Nothing Special   »   [go: up one dir, main page]

Zhou et al., 2023 - Google Patents

Sodium oligomannate electrostatically binds to Aβ and blocks its aggregation

Zhou et al., 2023

Document ID
3618200035607825019
Author
Zhou C
Zhang J
Luo X
Lian F
Zeng Y
Zhang Z
Zhang H
Zhang N
Publication year
Publication venue
The Journal of Physical Chemistry B

External Links

Snippet

GV-971 (sodium oligomannate) is a China Food and Drug Administration (CFDA)-approved drug for treating Alzheimer's disease, and it could inhibit Aβ fibril formation in vitro and in mouse studies. To elucidate the mechanisms for understanding how GV-971 modulates Aβ's …
Continue reading at pubs.acs.org (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2828—Prion diseases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells

Similar Documents

Publication Publication Date Title
Willbold et al. Amyloid-type protein aggregation and prion-like properties of amyloids
Hubin et al. Transient dynamics of Aβ contribute to toxicity in Alzheimer’s disease
Okada et al. Toxic amyloid tape: a novel mixed antiparallel/parallel β-sheet structure formed by amyloid β-protein on GM1 clusters
Broersen et al. The culprit behind amyloid beta peptide related neurotoxicity in Alzheimer's disease: oligomer size or conformation?
Salomon et al. Nicotine inhibits amyloid formation by the β-peptide
Sinha et al. A key role for lysine residues in amyloid β-protein folding, assembly, and toxicity
Karr et al. Cu (II) binding to monomeric, oligomeric, and fibrillar forms of the Alzheimer’s disease amyloid-β peptide
Zhang et al. Molecular understanding of Aβ-hIAPP cross-seeding assemblies on lipid membranes
Vosough et al. Characterization of homogeneous and heterogeneous amyloid-β42 oligomer preparations with biochemical methods and infrared spectroscopy reveals a correlation between infrared spectrum and oligomer size
Das et al. Looking at the disordered proteins through the computational microscope
Mannini et al. Stabilization and characterization of cytotoxic Aβ40 oligomers isolated from an aggregation reaction in the presence of zinc ions
Yamaguchi et al. A disulfide-linked amyloid-β peptide dimer forms a protofibril-like oligomer through a distinct pathway from amyloid fibril formation
Xu et al. Curcumin interacts with α-synuclein condensates to inhibit amyloid aggregation under phase separation
Dou et al. Phosphatidylcholine and phosphatidylserine uniquely modify the secondary structure of α-synuclein oligomers formed in their presence at the early stages of protein aggregation
Hou et al. Inhibition of β-amyloid channels with a drug candidate wgx-50 revealed by molecular dynamics simulations
Abelein et al. Molecular structure of Cu (II)-bound amyloid-β monomer implicated in inhibition of peptide self-assembly in Alzheimer’s disease
Foley et al. Trapping and characterization of nontoxic Aβ42 aggregation intermediates
de Almeida et al. Opposing effects of cucurbit [7] uril and 1, 2, 3, 4, 6-penta-O-galloyl-β-d-glucopyranose on amyloid β25–35 assembly
Mohamed et al. Tau derived hexapeptide AcPHF6 promotes beta-amyloid (Aβ) fibrillogenesis
Pham et al. Copper binding induces polymorphism in amyloid-β peptide: Results of computational models
Baram et al. Inhibitory activity of insulin on Aβ aggregation is restricted due to binding selectivity and specificity to polymorphic Aβ states
Korn et al. Incorporation of the nonproteinogenic amino acid β-methylamino-alanine affects amyloid β fibril properties and toxicity
Banerjee et al. Nanoscale infrared spectroscopy identifies structural heterogeneity in individual amyloid fibrils and prefibrillar aggregates
Williams et al. Soluble prion protein binds isolated low molecular weight amyloid-β oligomers causing cytotoxicity inhibition
Zhou et al. Sodium oligomannate electrostatically binds to Aβ and blocks its aggregation